Archer Aviation vs. Kraken Robotics: With Geopolitical Risk Rising, Which Defense Stock Wins?

The article argues Kraken Robotics is the better defense stock versus Archer Aviation, citing Kraken's 62.1% gross margin last year, expected 55%-60% gross margin this year, and prior profitability of CA$2.9 million net income. Kraken's 2025 sales were about CA$102 million ($72 million), and its pending Covelya acquisition could lift market cap toward $2 billion while expanding maritime technologies exposure. Archer is earlier stage, with only $1.6 million revenue in Q1 and a $618.2 million net loss, though it may begin commercial flights this year.

Analysis

KRKNF is the cleaner expression of the defense electrification theme because it is already monetizing into a real installed base, while ACHR is still mostly a financing-and-certification story. The market is likely underappreciating the second-order benefit of the Covelya combination: it expands Kraken from component exposure into a broader systems-integrator narrative, which should improve customer stickiness, raise cross-sell attach rates, and reduce single-program volatility. In a hardware business, that matters more than headline growth because it can support multiple turns of multiple expansion if gross margin stability holds.

The key short-term differentiator is balance-sheet timing. ACHR likely needs repeated capital raises before commercial scaling can be reflected in earnings power, which caps upside unless certification milestones arrive faster than expected. By contrast, KRKNF’s path to value creation is more incremental: defense procurement budgets, unmanned underwater systems adoption, and a plausible re-rating as revenue synergies from Anduril/Covelya show up over the next 2-4 quarters. The main risk is execution drag from integration or procurement slippage, not existential demand failure.

Consensus may be overpaying for the “faster TAM” story in ACHR while underweighting how defensible KRKNF’s niche is. If underwater drones become a meaningful procurement line item, the likely winners are the picks-and-shovels suppliers with proven margins, not the platform OEMs taking certification risk. The contrarian tell is that KRKNF’s current profitability gives it optionality to self-fund growth, while ACHR remains dependent on external capital markets, making it more vulnerable if risk appetite fades.

Key Decisions for Investors

• Long KRKNF on a 3-6 month horizon; favor entries on post-deal integration pullbacks. Risk/reward: lower upside than a pure pre-revenue story, but materially better downside protection given existing profitability and margin support.
• Short ACHR or buy put spreads against strength into certification headlines. Timeframe: 1-3 months. Thesis: any rally tied to commercialization optimism remains vulnerable to capital raise risk and delayed regulatory milestones.
• Pair trade: long KRKNF / short ACHR as a relative-value expression on defense-autonomy spend. This isolates the better balance-sheet and commercialization profile while reducing sector beta.
• If using options, prefer KRKNF call spreads rather than outright stock for a 6-12 month catalyst window; the setup benefits from steady multiple expansion if Anduril-linked demand flows through, but re-rating may be gradual.